Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 1 country.
Carla Fernanda Furtado GardaniEscola de Medicina, Programa de Pós-Graduaҫão em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, RS, Brazil.
Eduardo Luiz PedrazzaLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre 90619-900, RS, Brazil.
Victória Santos PazLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, Porto Alegre 90619-900, RS, Brazil.
Gabriele Goulart ZaniratiInstituto do Cérebro da PUCRS, InsCer, Avenida Ipiranga, 6690, Jardim Botânico, Porto Alegre 906010-000, RS, Brazil.
Jaderson Costa da CostaInstituto do Cérebro da PUCRS, InsCer, Avenida Ipiranga, 6690, Jardim Botânico, Porto Alegre 906010-000, RS, Brazil.ORCID 0000-0001-6776-1515
Roberta AndrejewDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Prof. Lineu Prestes, 748, Butantã, São Paulo 05508-000, SP, Brazil.
Henning UlrichDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Prof. Lineu Prestes, 748, Butantã, São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-2114-3815
Juliete Nathali SchollPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre 90035-003, RS, Brazil.ORCID 0000-0002-9509-2010
Fabrício FigueiróPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre 90035-003, RS, Brazil.ORCID 0000-0003-0899-6407
Liliana RockenbachEscola de Medicina, Programa de Pós-Graduaҫão em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, RS, Brazil.ORCID 0000-0001-6265-6564
Fernanda Bueno MorroneEscola de Medicina, Programa de Pós-Graduaҫão em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, RS, Brazil.ORCID 0000-0002-2709-2801
Pontifícia Universidade Católica do Rio Grande do Sul · BRInstituto do Cérebro · BRUniversidade de São Paulo · BRUniversidade Federal do Rio Grande do Sul · BR
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Financiadora de Estudos e Projetos 0366/2018National Council for Scientific and Technological Development 308012/2021-6National Council for Scientific and Technological Development 314687/2021-1National Council for Scientific and Technological Development 406396/2021São Paulo Research Foundation 2018/07366-4São Paulo Research Foundation 2019/24553-5
6 · The paper itself
Abstract
Prostate cancer (PC) is the most diagnosed tumor in males and ranks as the second leading cause of male mortality in the western world. The CD39 and CD73 enzymes play a crucial role in cancer regulation by degrading nucleotides and forming nucleosides. This study aimed to investigate the expression of the CD39 and CD73 enzymes as potential therapeutic targets for PC. The initial part of this study retrospectively analyzed tissue samples from 23 PC patients. Using the TissueFAXS
Indexed as
CD39CD73ectonucleotidasesextracellular vesiclesprostate cancer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer. · full record | OpenQuestion